Congenital hyperinsulinism (CHI) is a rare genetic disorder of the pancreas that results in excessive insulin secretion due to a mutation in genes regulating insulin secretion. This excessive insulin causes hypoglycemia (low blood sugar) right after birth or within the first few months of life for many infants. CHI is caused by abnormal cells known as beta cells in the pancreas that produce too much insulin.
The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 217.74 Mn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global congenital hyperinsulinism treatment market is expected to be driven by the rising number of patients opting for surgical therapeutics for treatment such as pancreatectomy and pancreatic resection. As per statistics provided by the National Library of Medicine, nearly 1 in 50,000 newborns are affected by congenital hyperinsulinism. While the disease can be managed with medical management alone in several cases, severe cases may require surgical intervention to remove overactive beta cells from the pancreas. The market is further propelled by the growing research and development activities focused on developing novel targeted treatment approaches.
Market Dynamics:
Rising Adoption of Surgical Therapeutics: As mentioned in the heading, the growing preference for surgical options such as pancreatectomy and pancreatic resection for severe cases of CHI is driving the growth of the congenital hyperinsulinism treatment market. The surgical approach offers definitive cure in comparison to lifelong medical management in severe cases by removing overactive beta cells from the pancreas.
Increasing Research Activities: Extensive research over the past decade exploring the genetic causes of CHI and developing targeted treatment approaches is also fueling the market growth. Biotech companies are investing in developing gene therapies and novel drugs that selectively target the beta cells responsible for overproduction of insulin. Such targeted therapies promise better outcomes than whole pancreas resection and are therefore gaining attention.
Segment Analysis
The congenital hyperinsulinism treatment market has been segmented based on types, drug type, and end users. The type segment is further divided into diffuse and focal congenital hyperinsulinism. The diffuse type congenital hyperinsulinism segment dominates the market and accounts for around 70% share as it is more common and difficult to treat compared to the focal type. Based on drug type, the market is categorized into diazoxide, octreotide, everolimus, and somatostatin analogs. The diazoxide segment holds the largest market share as it is the first line treatment drug for congenital hyperinsulinism. Based on end users, the market is segmented into hospitals, clinics, and others. The hospitals segment holds the largest share due to high patient footfall and availability of advanced treatment facilities.
PEST Analysis
Political: The congenital hyperinsulinism treatment market is positively affected by favourable reimbursement policies for medical conditions from various public and private payers.
Economic: Rising healthcare expenditure and increasing disposable income levels in developing countries are driving market growth. However, high treatment costs can restrain the market.
Social: Growing public awareness about rare diseases and availability of advanced treatment options is boosting adoption. However, social stigma associated with certain rare conditions act as a challenge.
Technological: Development of advanced drugs tailored for diseases, minimally invasive procedures, and genome sequencing techniques are offering new opportunities for effective treatment and diagnosis of congenital hyperinsulinism.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth. The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030.
Regional analysis comprises the North America region dominates the market and accounts for around 40% share due to increasing access to advanced healthcare facilities and high healthcare expenditure levels. Europe is the second largest market due to growing public awareness about rare diseases and favorable government initiatives. The Asia Pacific region is expected to be the fastest growing market owing to rising medical tourism, improved access to healthcare facilities and increasing disposable incomes.
Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices. Key players are focusing on new product launches with better efficacy and minimal side effects to strengthen their market position.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.